Nanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugs

Simple item page
dc.contributor.authorLee, KWYen_AU
dc.contributor.authorNguyen, THen_AU
dc.contributor.authorHanley, TLen_AU
dc.contributor.authorBoyd, BJen_AU
dc.date.accessioned2009-06-11T06:28:24Zen_AU
dc.date.accessioned2010-04-30T05:07:36Zen_AU
dc.date.available2009-06-11T06:28:24Zen_AU
dc.date.available2010-04-30T05:07:36Zen_AU
dc.date.issued2009-01-05en_AU
dc.date.statistics2009-01-05en_AU
dc.description.abstractNanostructured lipid-based liquid crystalline systems have been proposed as sustained oral drug delivery systems, but the interplay between their intrinsic release rates, susceptibility to digestive processes, and the manner in which these effects impact on their application in vivo, are not well understood. In this study, two different bicontinuous cubic phases, prepared from glyceryl monooleate and phytantriol, and a reversed hexagonal phase formed by addition of a small amount of vitamin E to phytantriol (Q(11 GMO). Q(11 PHYT) and H11 PHYT+VitEA, respectively) were prepared. The release kinetics for a number of model hydrophilic drugs with increasing molecular weights (glucose, Allura Red and FITC-clextrans) was determined in in vitro release experiments. Diffusion-controlled release was observed in all cases as anticipated from previous studies with liquid crystalline systems, and it was discovered that the release rates of each drug decreased as the matrix was changed from Q(11 GMO) to Q(11 PHYT) to H-11 PHYT VitEA. Formulations containing C-14-glucose, utilized as a rapidly absorbed marker of drug release, were then orally administered to rats to determine the relative in vivo absorption rates from the different formulations. The results showed a trend by which the rate of absorption of C-14-glucose followed that observed in the corresponding in vitro release studies, providing the first indication that the nanostructure of these materials may provide the ability to tailor the absorption kinetics of hydrophilic drugs in vivo, and hence form the basis of a new drug delivery system. © 2008, Elsevier Ltd.en_AU
dc.identifier.citationLee, K. W. Y., Nguyen, T.- H., Hanley, T., & Boyd, B. J. (2009). Nanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugs. International Journal of Pharmaceutics, 365(1-2), 190-199. doi:10.1016/j.ijpharm.2008.08.022en_AU
dc.identifier.govdoc1487en_AU
dc.identifier.issn0378-5173en_AU
dc.identifier.issue1-2en_AU
dc.identifier.journaltitleInternational Journal of Pharmaceuticsen_AU
dc.identifier.pagination190-199en_AU
dc.identifier.urihttp://dx.doi.org/10.1016/j.ijpharm.2008.08.022en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/1342en_AU
dc.identifier.volume365en_AU
dc.language.isoenen_AU
dc.publisherElsevieren_AU
dc.subjectLiquid crystalsen_AU
dc.subjectAbsorptionen_AU
dc.subjectPhase studiesen_AU
dc.subjectKineticsen_AU
dc.subjectNanostructuresen_AU
dc.subjectRelease limitsen_AU
dc.titleNanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugsen_AU
dc.typeJournal Articleen_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal Articles